Drug ‘could herald precision medicine’ in multiple myeloma
Results from an international trial of venetoclax may prove to be a watershed, a leading haematological oncologist says
A trial of the oral BCL-2 inhibitor venetoclax in a triple therapy regimen for multiple myeloma suggests certain patients might benefit from the new agent, despite an excess of fatal infections.
In the phase 3 international BELLINI trial, which included Australian patients, 291 people with relapsed or refractory disease (median age 66, 52% male) were randomised 2:1 to 800mg venetoclax or placebo daily.
